Evidence map›Paper›PMID 39030461›Full record

ArticleIrish journal of medical science2024

Treatment of a STAT5b::RARα positive case of APL in a patient not eligible for intensive chemotherapy.

Jason Patterson, Kathryn Clarke, Katya Mokretar, Manisha Maurya, Amy Logan, Nicholas Cunningham, Mark Catherwood, Mary Frances McMullin

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Irish journal of medical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jason PattersonDepartment of Haematology, Belfast City Hospital, Belfast, Northern Ireland, UK.
Kathryn ClarkeDepartment of Haematology, Belfast City Hospital, Belfast, Northern Ireland, UK.
Katya MokretarCancer Genetics, Guy's Hospital, Synnovis, London, UK.
Manisha MauryaPrecision Medicine Centre, Queen's University Belfast, Belfast, Northern Ireland, UK.
Amy LoganRegional Molecular Diagnostics Service, Belfast City Hospital, Belfast, Northern Ireland, UK.
Nicholas CunninghamDepartment of Haematology, Belfast City Hospital, Belfast, Northern Ireland, UK.
Mark CatherwoodRegional Molecular Diagnostics Service, Belfast City Hospital, Belfast, Northern Ireland, UK.
Mary Frances McMullinCentre for Medical Education, Queen's University Belfast, Belfast, Northern Ireland, UK. M.Mcmullin@qub.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute promyelocytic leukaemia (APL) with a STAT5b::RARα gene fusion is an extremely rare subtype of APL characterised by resistance to conventional therapies and extremely poor prognosis. This case highlights that whilst APL with variant RARα translocations are rare, they do pose significant challenges both diagnostically and in their clinical management. This case, in the first instance, demonstrates the importance of using a combination of molecular techniques including next generation sequencing (NGS) for diagnosis particularly in morphological and immunophenotypic typical APL which appears negative by confirmatory testing. Secondly, our patient represents, to the best of our knowledge, the first documented example of this rare disease that has been managed with, and shown sensitivity to low-dose cytarabine (LDAC) in combination with venetoclax (Ven). This case demonstrates that although treatment options are extremely limited for patients not eligible for intensive chemotherapy non-intensive options do show increasing promise.

Indexed as

Leukemia, Promyelocytic, AcuteSTAT5 Transcription FactorSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicCytarabineHigh-Throughput Nucleotide SequencingHumansOncogene Proteins, FusionRetinoic Acid Receptor alphaBridged Bicyclo Compounds, HeterocyclicCytarabineOncogene Proteins, FusionRARA protein, humanRetinoic Acid Receptor alphaSTAT5B protein, humanSTAT5 Transcription FactorSulfonamidesvenetoclaxAcute promyelocytic leukaemiaLow-dose cytarabineNext generation sequencingVariantVenetoclax

Identifiers

PMID39030461
PMCPMC11666630

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.